Moderna and Merck's Melanoma Vaccine Shows Promising Trial Results

Moderna and Merck have announced promising results from their joint mRNA vaccine trial. The therapy, designed to prevent the return of melanoma, has shown success in an FDA-approved trial.

The personalized mRNA therapies were tested on patients with a history of melanoma, and researchers are optimistic that the results could be applied to other cancers.

While there is no specific mention of the number of participants or the exact percentage of successful outcomes, the collaboration between Moderna and Merck has brought new hope for cancer treatment.